VivoSeq
Cardiovascular

Uncontrolled Hypertension

3

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Uncontrolled Hypertension is an early-stage landscape with 3 programs across 3 companies. The most active players are Retension Pharmaceuticals. Inc., Eli Lilly, AstraZeneca. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Retension Pharmaceuticals. Inc.

2 programs

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Not yet recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Baxdrostat on Ambulatory Blood Pressure in Chinese Participants With Uncontrolled Hypertension on Two or More Antihypertensive Medications Without Diuretics
Not yet recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT07686120·286 enrolled
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Recruiting·RRetension Pharmaceuticals. Inc.·Phase 2·NCT07142356·280 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)